Publication: 274

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Citation:: J Clin Oncol vol 26 (6) 848-55

Year:: 2008
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 803
Children:: None

Program:: OGC
Primary Committee:: Respiratory
Sec. Committees:

Pharmas:
Grants:: CA03927, CA16450, CA31946, CA31983, CA33601, CA41287, CA45389, CA45418, CA47577, CA77658

Corr. Author:
Authors:: Martin J Edelman Dee Watson Xiaofei Wang Carl Morrison Robert A Kratzke Scott Jewell Lydia Hodgson Ann M Mauer Ajeet Gajra Gregory A Masters Michelle Bedor Everett E Vokes Mark J Green

Networks:

Study: CALGB-30203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carboplatin, Carcinoma, Non-Small-Cell Lung, Celecoxib, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Deoxycytidine, Disease-Free Survival, Drug Administration Schedule, Eicosanoids, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Humans, Hydroxyurea, Immunohistochemistry, Lipoxygenase Inhibitors, Logistic Models, Lung Neoplasms, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prognosis, Prospective Studies, Pyrazoles, Sulfonamides, Up-Regulation